Cargando…

A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features

Detalles Bibliográficos
Autores principales:	Yesilkaya, Umit Haluk, Sen, Meltem, Tasdemir, Busra Guney
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492001/ https://www.ncbi.nlm.nih.gov/pubmed/34632429 http://dx.doi.org/10.1016/j.bbih.2021.100363

Ejemplares similares

SARS-CoV-2-associated first episode of acute mania with psychotic features
por: Sen, Meltem, et al.
Publicado: (2021)

New variants and new symptoms in COVID-19: First episode psychosis and Cotard's Syndrome two months after infection with the B.1.1.7 variant of coronavirus
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2022)

Gender differences in first episode psychotic mania
por: Cotton, Sue M, et al.
Publicado: (2013)

COVID-19-related cognitive dysfunction may be associated with transient disruption in the DLPFC glutamatergic pathway
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2021)

Neurosarcoidosis masquerading as mania with psychotic features—A case report
por: Shoib, Sheikh, et al.
Publicado: (2023)

Psychotic mania as the solitary manifestation of neurosyphilis
por: Seo, Eun Hyun, et al.
Publicado: (2018)

Corticosteroid induced mania with psychotic symptoms
por: Tavares, F. Gomes, et al.
Publicado: (2021)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

First Episode Mania at 75 Years of Age
por: Aggarwal, Ashish, et al.
Publicado: (2010)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Deranged Serum Cholesterol Levels in First Episode Mania
por: Kavoor, Anjana Rao, et al.
Publicado: (2014)

Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania
por: Ikeda, Masashi, et al.
Publicado: (2022)

(29) Case Report of New Onset Mania With Psychotic Features Following COVID-19 Vaccination
por: Pomerantz, Amanda, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
por: Inoue, Sumito, et al.
Publicado: (2022)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Psychotic mania in glucose-6-phosphate-dehydrogenase-deficient subjects
por: Bocchetta, Alberto
Publicado: (2003)

Gamma activity model for treatment-resistant bipolar psychotic mania
por: Kumar, Shashi Ranjan, et al.
Publicado: (2015)

Acute mania with psychotic symptom in post COVID-19 patient
por: Shanmugam, Sridevi, et al.
Publicado: (2021)

Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
por: Gulmez, Ruveyda, et al.
Publicado: (2022)

Cognitive functioning following stabilisation from first episode mania
por: Daglas, Rothanthi, et al.
Publicado: (2017)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Symptomatological Features of Patients with and without Ecstasy Use during Their First Psychotic Episode
por: Rugani, Fabio, et al.
Publicado: (2012)

Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
por: Palacios-Garrán, Roberto, et al.
Publicado: (2022)

Neuroimmune correlates of the nervous system involvement of COVID-19: A commentary
por: Yesilkaya, Umit Haluk, et al.
Publicado: (2020)

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan
por: Namiki, Takahiro, et al.
Publicado: (2022)

Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia
por: Almohaya, Abdulellah M., et al.
Publicado: (2021)

Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers
por: Lee, Dong Yeop, et al.
Publicado: (2023)

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
por: Walton, Muireann, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m5q0anhshgcpduraumg03pgg39